Literature DB >> 34247278

The Classification, Pathogenesis, Diagnostic Workup, and Management of Urticaria: An Update.

Marcus Maurer1, Torsten Zuberbier2, Martin Metz2.   

Abstract

Wheals and angioedema are the signature signs of urticaria, and itch is the key symptom. Urticaria, in most patients, is acute and resolves within days (acute urticaria, AU). Chronic urticaria (CU) can be of long duration and results not only in severely impaired quality of life but also has a socioeconomic impact due to work productivity impairment. In some patients with CU, the wheals and angioedema are induced exclusively by defined and definite triggers (chronic inducible urticaria, CIndU). In most patients with CU, wheals and angioedema develop unprompted, spontaneously (chronic spontaneous urticaria, CSU). The management of CU aims for the complete control and absence of its signs and symptoms. This is achieved, in most patients, by prophylactic treatment until spontaneous remission occurs. Modern, second-generation H1-antihistamines are the first-line therapy, with the option of updosing to fourfold, and omalizumab is used when this fails.
© 2021. Springer Nature Switzerland AG.

Entities:  

Keywords:  Angioedema; Chronic; Hives; Inducible; Itch; Mast Cell; Pruritus; Spontaneous; Urticaria; Wheals

Year:  2021        PMID: 34247278     DOI: 10.1007/164_2021_506

Source DB:  PubMed          Journal:  Handb Exp Pharmacol        ISSN: 0171-2004


  1 in total

1.  Multicentric and Observational Study of Omalizumab for Chronic Spontaneous Urticaria in Real-Life in Colombia.

Authors:  Elizabeth García-Gómez; Edgardo Chapman; María Beatriz García-Paba; Jaime Ocampo-Gómez; Eduardo Egea-Bermejo; Gloria Garavito-De Egea; Luis Fang; Mauricio Sarrazola; Jorge Mario Sánchez-Caraballo; Carlos Serrano-Reyes; Diana Lucia Silva-Espinosa; Dolly Vanessa Rojas-Mejía; Sergio M Moreno
Journal:  Front Allergy       Date:  2022-05-20
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.